Dr. Kenneth Emancipator, MD, DABP to Give Keynote at GTCbio’s Biomarker summit. Dr. Kenneth Emancipator will discuss, “Programmed Cell Death 1 Ligand” (PD-L1) as a Companion Diagnostic for Pembrolizumab” at Biomarker Summit.
BigNews.Biz - Jan 04,2017 - Kenneth Emancipator, MD, DABP Executive Medical Director and Head of Companion Diagnostics for Merck & Company, will give a keynote presentation on ““Programmed Cell Death 1 Ligand” (PD-L1) as a Companion Diagnostic for Pembrolizumab” at GTCBio’s Biomarker Summit to be held on March 20-22, 2017 in San Diego, CA.
Participants will learn
• How rigorous clinical epidemiologic techniques were applied in a real-life setting;
• How personalized medicine can facilitate drug development;
• The unexpected consequences of taking a personalized medicine approach in a highly competitive environment;
• The challenges of deploying a companion diagnostic to healthcare providers worldwide.
This Summit will also include four following conferences:
A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.